Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Other Non-Current Assets data on record, last reported at $2.5 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 10308.33% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.5 million, up 10308.33%, while the annual FY2025 figure was $2.5 million, 10308.33% up from the prior year.
  • Other Non-Current Assets reached $2.5 million in Q4 2025 per AMLX's latest filing, roughly flat from $2.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.5 million in Q3 2025 and bottomed at $11000.0 in Q1 2025.
  • Average Other Non-Current Assets over 5 years is $676125.0, with a median of $471000.0 recorded in 2022.
  • The widest YoY moves for Other Non-Current Assets: up 10308.33% in 2025, down 97.77% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $200000.0 in 2021, then skyrocketed by 133.0% to $466000.0 in 2022, then skyrocketed by 50.43% to $701000.0 in 2023, then crashed by 96.58% to $24000.0 in 2024, then skyrocketed by 10308.33% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $2.5 million in Q4 2025, $2.5 million in Q3 2025, and $11000.0 in Q1 2025.